Prostate Cancer
An review of 8 studies showed prostate cancer diagnosis increased the risk for suicide by 2.01 (2)
In nmCRPC, at 2 years 1/3 of men have bone mets and the average metastasis free survival is approximately 30 months. (3)
The PCPT risk calculator gives risk of prostate cancer based on parameters (4) and the updated calculator is more accurate (5) The PCCI is an estimator of prostate cancer mortality. (6)
NEJM in 2023 publishes a nice review of PSA screening. (7)
In nmCRPC, at 2 years 1/3 of men have bone mets and the average metastasis free survival is approximately 30 months. (3)
The PCPT risk calculator gives risk of prostate cancer based on parameters (4) and the updated calculator is more accurate (5) The PCCI is an estimator of prostate cancer mortality. (6)
NEJM in 2023 publishes a nice review of PSA screening. (7)
- 2nd leading cause of cancer death in men(1)
REFERENCES
- Siegel, Rebecca L., et al. "Cancer statistics, 2017." CA: a cancer journal for clinicians 67.3 (2017): 177-193.
- Guo, Zhenlang, et al. "Incidence and risk factors of suicide after a prostate cancer diagnosis: a meta-analysis of observational studies." Prostate cancer and prostatic diseases (2018): 1.
- Smith, M. R., et al. “Natural History of Rising Serum PSA in Men with Castrate Nonmetastatic Prostate Cancer.” Journal of Clinical Oncology, vol. 23, 2005, pp. 4514–4514.
- http://riskcalc.org/PCPTRC/
- http://riskcalc.org:3838/PBCG/
- Daskivich, Timothy J., et al. “External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.” The Journal of Urology, vol. 202, no. 3, 2019, pp. 518–524.
- Screening for Prostate Cancer. N Engl J Med 2023; 388:1405-1414
DOI: 10.1056/NEJMcp2209151